The "No Fentanyl on Social Media Act" mandates that the Federal Trade Commission (FTC), in coordination with the Secretary of Health and Human Services (acting through the FDA Commissioner) and the Administrator of the Drug Enforcement Administration (DEA), submit a comprehensive report to relevant congressional committees within one year of the Act's enactment. This report, which must also be made publicly available, will focus on the ability of minors to access fentanyl, including pressed pills, through social media platforms. The required report must cover several key areas, including the **prevalence and ease of access** for minors to obtain fentanyl from drug sellers on social media, and the **impact** of such access on minors, encompassing health and physical safety risks. It will also examine how drug sellers utilize social media platforms for marketing, selling, and distributing fentanyl to minors, and how platform design features contribute to this access. Furthermore, the report will assess the effectiveness of current practices and policies implemented by social media platforms, law enforcement, and the medical community to address these issues, culminating in **recommendations for Congress** to eliminate minors' access to fentanyl on these platforms. The FTC is required to consult with various stakeholders, including parents, social media platforms, law enforcement, and medical professionals, during the report's development, with provisions for redacting sensitive law enforcement information.